secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055598
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data
----------------------------------------------------------------

- Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.
- CX-904 (EGFRxCD3) shows favorable safety; 2 of 6 pancreatic patients with confirmed partial responses.
- CX-2051 (EpCAM ADC) first patient dosed Apr 2024; first dose cohort cleared; initial data H1 2025.
- CX-801 (IFNα2b) to start Phase 1 in Q2 2024; collaboration with Merck for KEYTRUDA combo.
- Achieved $10M in Astellas milestones for two T-cell engager programs; Dr. Zhen Su appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/0000950170-24-055598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024055598/ctmx-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer